Back to search results

A Study of LY4005130 for Severe Alopecia Areata

This study is testing a drug called LY4005130 for adults with severe alopecia areata (hair loss). Researchers want to see how well LY4005130 works compared to a placebo (an inactive substance) and what side effects it might have. You could be eligible if you are between 18 and 50 years old and have severe alopecia areata, meaning you have lost 50% to 90% of your scalp hair. The main goal is to see if participants achieve 20% or less scalp hair loss after 24 weeks. The study drug or placebo will be given through an IV (into a vein). The study is planned to include 60 participants.

Study design
This is an interventional study comparing LY4005130 to a placebo in 60 adult participants. The phase of the study is not specified.
What's involved
You would receive the study drug or placebo intravenously. The study will last approximately 48 weeks, including a screening period.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome for hair regrowth is measured at Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07533006

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

Recruiting
PHASE2Ages 18–50InterventionalTreatment
Eli Lilly and Company
~60 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:LY4005130Placebo

At a glance

Recruiting sites
17 of 30 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to (≤) 20
Measured over Week 24

Conditions

Alopecia Areata

Explore related trials

Alopecia

Where it's being run

30 sites across 13 states
South Korea5
Canada4
China4
Poland4
California3
United Kingdom3
Florida1
Massachusetts1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
1-317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have severe Alopecia Areata (AA) that meets all of the following criteria:
Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
Agree not to use any AA treatments during the study

Exclusion

Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
Are currently experiencing other forms of alopecia
Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
Have received oral JAK Inhibitors in the past
Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness

What this trial measures

  • Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Less than or Equal to (≤) 20Week 24